BR112023010517A2 - 5'-o-fenilacetil uridina e seu uso terapêutico - Google Patents
5'-o-fenilacetil uridina e seu uso terapêuticoInfo
- Publication number
- BR112023010517A2 BR112023010517A2 BR112023010517A BR112023010517A BR112023010517A2 BR 112023010517 A2 BR112023010517 A2 BR 112023010517A2 BR 112023010517 A BR112023010517 A BR 112023010517A BR 112023010517 A BR112023010517 A BR 112023010517A BR 112023010517 A2 BR112023010517 A2 BR 112023010517A2
- Authority
- BR
- Brazil
- Prior art keywords
- uridine
- phenylacetyl
- therapeutic use
- hepatic
- phenylacetate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Saccharide Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063119764P | 2020-12-01 | 2020-12-01 | |
| PCT/US2021/061053 WO2022119784A1 (en) | 2020-12-01 | 2021-11-30 | 5'-o-phenylacetyluridine and therapeutic use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023010517A2 true BR112023010517A2 (pt) | 2024-02-06 |
Family
ID=81854225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023010517A BR112023010517A2 (pt) | 2020-12-01 | 2021-11-30 | 5'-o-fenilacetil uridina e seu uso terapêutico |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230416292A1 (https=) |
| EP (2) | EP4255563B1 (https=) |
| JP (1) | JP2023551467A (https=) |
| KR (1) | KR20230112118A (https=) |
| CN (1) | CN116782912A (https=) |
| AU (1) | AU2021391411A1 (https=) |
| BR (1) | BR112023010517A2 (https=) |
| CA (1) | CA3199559A1 (https=) |
| DK (1) | DK4255563T3 (https=) |
| FI (1) | FI4255563T3 (https=) |
| IL (1) | IL303100A (https=) |
| LT (1) | LT4255563T (https=) |
| MX (1) | MX2023006343A (https=) |
| PL (1) | PL4255563T3 (https=) |
| PT (1) | PT4255563T (https=) |
| WO (1) | WO2022119784A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT4210709T (pt) | 2020-09-14 | 2026-02-04 | Pharma Cinq Llc | 2¿,3¿‐diacetiluridina substituída com acetoacetilo na posição 5¿ |
| TW202317144A (zh) * | 2021-06-14 | 2023-05-01 | 美商維納拓爾斯製藥公司 | 口服生物可利用的核苷類似物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0346108A3 (en) * | 1988-06-09 | 1991-04-24 | The Wellcome Foundation Limited | Anti-infective nucleosides |
| JP2526414B2 (ja) | 1994-05-20 | 1996-08-21 | 工業技術院長 | 制ガン剤エステル化合物及びその製造方法 |
| JP4408450B2 (ja) * | 1994-07-01 | 2010-02-03 | ウェルスタット セラピューティクス コーポレイション | 全身性炎症および炎症性肝炎の処置のためのピリミジンヌクレオチド前駆体 |
| EP1808177B1 (en) * | 1999-02-23 | 2018-08-08 | The Regents of The University of California | Methods of treatment of mitochondrial disorders |
| SI2153870T1 (sl) * | 2004-11-26 | 2014-05-30 | Ucl Business Plc | Sestavki, ki obsegajo ornitin in fenilacetat ali fenilbutirat, za zdravljenje hepatitične encefalopatije |
| GB0426141D0 (en) * | 2004-11-26 | 2004-12-29 | Ucl Biomedica Plc | Treatment |
| PT2922576T (pt) * | 2012-11-21 | 2018-01-24 | Horizon Therapeutics Llc | Métodos de administração e avaliação de fármacos sequestradores de azoto para o tratamento de encefalopatia hepática |
| PL3182980T3 (pl) * | 2014-08-19 | 2021-04-19 | Wellstat Therapeutics Corporation | Leczenie chorób niedoboru glikozylacji |
| AU2019215105B2 (en) * | 2018-02-01 | 2024-12-19 | Pharma Cinq, Llc | Compositions and devices for systemic delivery of uridine |
| WO2022089612A1 (zh) * | 2020-10-30 | 2022-05-05 | 上海岸阔医药科技有限公司 | 尿苷衍生物在制备药物中的应用 |
-
2021
- 2021-11-30 US US18/036,744 patent/US20230416292A1/en active Pending
- 2021-11-30 BR BR112023010517A patent/BR112023010517A2/pt unknown
- 2021-11-30 EP EP21901291.1A patent/EP4255563B1/en active Active
- 2021-11-30 WO PCT/US2021/061053 patent/WO2022119784A1/en not_active Ceased
- 2021-11-30 KR KR1020237017758A patent/KR20230112118A/ko active Pending
- 2021-11-30 AU AU2021391411A patent/AU2021391411A1/en active Pending
- 2021-11-30 PL PL21901291.1T patent/PL4255563T3/pl unknown
- 2021-11-30 CA CA3199559A patent/CA3199559A1/en active Pending
- 2021-11-30 MX MX2023006343A patent/MX2023006343A/es unknown
- 2021-11-30 LT LTEPPCT/US2021/061053T patent/LT4255563T/lt unknown
- 2021-11-30 FI FIEP21901291.1T patent/FI4255563T3/fi active
- 2021-11-30 PT PT219012911T patent/PT4255563T/pt unknown
- 2021-11-30 EP EP25219839.5A patent/EP4711007A3/en active Pending
- 2021-11-30 DK DK21901291.1T patent/DK4255563T3/da active
- 2021-11-30 IL IL303100A patent/IL303100A/en unknown
- 2021-11-30 JP JP2023532125A patent/JP2023551467A/ja active Pending
- 2021-11-30 CN CN202180080169.0A patent/CN116782912A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PL4255563T3 (pl) | 2026-04-20 |
| EP4255563B1 (en) | 2025-12-31 |
| WO2022119784A1 (en) | 2022-06-09 |
| JP2023551467A (ja) | 2023-12-08 |
| AU2021391411A1 (en) | 2023-07-20 |
| IL303100A (en) | 2023-07-01 |
| EP4711007A2 (en) | 2026-03-18 |
| PT4255563T (pt) | 2026-03-24 |
| MX2023006343A (es) | 2023-06-12 |
| CN116782912A (zh) | 2023-09-19 |
| KR20230112118A (ko) | 2023-07-26 |
| EP4255563A1 (en) | 2023-10-11 |
| FI4255563T3 (fi) | 2026-03-13 |
| EP4711007A3 (en) | 2026-04-01 |
| AU2021391411A9 (en) | 2024-07-18 |
| CA3199559A1 (en) | 2022-06-09 |
| EP4255563A4 (en) | 2024-09-11 |
| DK4255563T3 (da) | 2026-03-16 |
| LT4255563T (lt) | 2026-04-10 |
| US20230416292A1 (en) | 2023-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023000204A1 (es) | Composiciones dirigidas al músculo genomodificadas | |
| AR044007A1 (es) | Metodos para el tratamiento de la enfermedad de parkinson | |
| BR112021026395A2 (pt) | Compostos de 2,3-di-hidroquinazolina como inibidores de nav1.8 | |
| BR112023010517A2 (pt) | 5'-o-fenilacetil uridina e seu uso terapêutico | |
| CO2019006292A2 (es) | Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares | |
| CO2021005070A2 (es) | Inhibición de la proteasa 30 específica de la ubiquitina (usp30) | |
| AR025111A1 (es) | Metodos y composiciones para tratar trastornos de ansiedad generalizada | |
| CO2019010078A2 (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 | |
| BR112022003527A2 (pt) | Cianopirrolidinas substituídas com atividade como inibidores de usp30 | |
| BR0313371A (pt) | Composto, uso de um composto e método de tratamento de doença | |
| CO2023013465A2 (es) | Composiciones y métodos para inhibir cetohexoquinasa (khk) | |
| MX2022012575A (es) | Compuestos para usarse para tratar la enfermedad de huntington. | |
| PE20240725A1 (es) | Anticuerpos anti-nectina-4 y usos de los mismos | |
| CL2023003518A1 (es) | Nuevas sales y formas cristalinas de sales de n,n-dimetiltriptamina | |
| UY39510A (es) | Compuestos macrocíclicos y métodos para usarlos | |
| ECSP22044525A (es) | Terapia de combinaci?n que comprende un inhibidor de alk2 y un inhibidor de jak2 | |
| CR20210514A (es) | USO DE REBOXETINA PARA EL TRATAMIENTO DE NARCOLEPSIA (Divisional 2021-0183) | |
| MX2022011173A (es) | Tratamiento de infeccion por coronavirus. | |
| CO2022000266A2 (es) | Inhibidores de enzimas | |
| BR112022019722A2 (pt) | N-cianopirrolidinas com atividade como inibidores de usp30 | |
| MX2024012438A (es) | Inhibición de la histona deacetilasa 6 (hdac6) | |
| MX2022014577A (es) | Gel intestinal de levodopa y carbidopa y metodos de uso. | |
| BR0313413A (pt) | Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer | |
| CO2023013442A2 (es) | Inhibidores de integrina alpha v beta 6 y alpha v beta 1 y sus usos | |
| BR112022011834A2 (pt) | Derivado de pirimidina e uso do mesmo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: PHARMA CINQ, LLC (US) |